Baseline characteristics of individuals with T2DM from the Clinical Practice Research Datalink initiating GLP-1 RAs (n=589*), UK
| N (%) | |
| Total | 589* (100) |
| Age (years) | |
| <45 | 127 (21.6) |
| 45–54 | 192 (32.6) |
| 55–64 | 168 (28.5) |
| 65–74 | 88 (14.9) |
| 75+ | 14 (2.4) |
| Median (Q1, Q3) | 54 (46, 61) |
| Mean (SD) | 53 (11.5) |
| Gender | |
| Female | 332 (56.4) |
| Male | 257 (43.6) |
| Dose frequency | |
| Daily† | 465 (78.9) |
| Weekly‡ | 124 (21.1) |
| Comorbidities | |
| Microvascular complications | |
| Retinopathy | 55 (9.3) |
| Neuropathy | 25 (4.2) |
| Nephropathy | 10 (1.7) |
| Macrovascular complications | |
| Cardiovascular disease | 167 (28.4) |
| Chronic kidney disease | 49 (8.3) |
| Congestive heart failure | 15 (2.5) |
| Other diseases | |
| Arrhythmia | 35 (5.9) |
| Depression | 281 (47.7) |
| Angina | 34 (5.8) |
| Hyperlipidemia | 154 (26.1) |
| Malignant neoplasms | 39 (6.6) |
| Hypoglycemia | 4 (0.7) |
| Hypertension | 401 (68.1) |
| Body mass index (kg/m2), n=527 | |
| <30 | 23 (3.9) |
| 30–34.9 | 84 (14.3) |
| 35–39.9 | 125 (21.2) |
| 40–44.9 | 141 (23.9) |
| ≥45 | 154 (26.1) |
| Missing | 62 (10.5) |
| Mean (SD) | 41.7 (8.2) |
| Median (q1, q3) | 41.2 (35.8, 46.4) |
| Laboratory assessments | N (%) | Mean (SD) | Median (Q1, Q3) |
| HbA1c (mmol/mol), n=576 | 576 (97.8) | 49.4 (36.1) | 57.0 (9.1, 77.0) |
| eGFR (mL/min), n=168 | 168 (28.5) | 74.5 (14.7) | 77.5 (64.0, 86.0) |
| Triglycerides (mg/dL), n=451 | 451 (76.6) | 221.8 (155.6) | 177.1 (132.9, 260.4) |
| LDL-C (mg/dL), n=399 | 399 (67.7) | 97.9 (39.2) | 88.9 (69.6, 123.7) |
| HDL-C (mg/dL), n=509 | 509 (86.4) | 43.0 (10.9) | 42.5 (34.8, 48.7) |
| Total cholesterol (mg/dL), n=552 | 552 (93.7) | 179.7 (46.0) | 174.0 (146.9, 208.8) |
| SBP (mm Hg), n=456 | 456 (77.4) | 132.5 (15.2) | 130.0 (121.0, 140.0) |
| DBP (mm Hg), n=456 | 456 (77.4) | 80.8 (9.3) | 80.0 (76.0, 85.5) |
*n=589 unless otherwise specified in the table.
†Of those on a daily regimen, 46.0% were initiated on exenatide, 35.3% on liraglutide, and 18.7% on lixisenatide.
‡Of those on a weekly regimen, 81.5% were initiated on exenatide and 18.5% were on dulaglutide.
DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.